ClinicalTrials.gg
RecruitingNCT06205576Updated Jan 16, 2024

ACOART AVF RENEW: A Post Market Clinical Study

An interventional study of DCB catheter in Stenosis of Native Hemodialysis Arteriovenous Fistulas, sponsored by Acotec Scientific Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-01-16.

Sponsored by Acotec Scientific Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Registered 10 months after the study started (first participant enrolled Feb 2023, registered Jan 2024).
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
164
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Arteriovenous Fistula with a site in China — 6 open to participants now, 7 under way, none of them phase 3. Arteriovenous Fistula · China.

Planned enrollment
9th of 14
164 · median 184
Started
2023
the only one that year
No phase
13 of 20
4 open now
Registered
14th of 20
by date
Lead sponsor
2 of 20
Acotec Scientific Co., Ltd

Among the 20 studies in Arteriovenous Fistula with a site in China, this one is the 9th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2023, is one of 13 with no phase, and was the 14th registered.

Arteriovenous Fistula

248 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.

Browse Arteriovenous Fistula studies →

Open to participants now

6 of the 20 studies in Arteriovenous Fistula with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Arteriovenous Fistula studies recruiting now, 13 (48%) set no upper age limit and 4 (15%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Arteriovenous Fistula with a site in China, or all of them as a file.
02

Study summary

The objective of this prospective,multi-center,single arm study is to obtain further data on the safety and performance of the Acotec Orchid&Dhalia Drug-coated Balloon catheters for the treatment of for the obstructive lesions in the native Arteriovenous Dialysis Fistulae (AVF).

03

Conditions studied

  • Stenosis of Native Hemodialysis Arteriovenous Fistulas
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is ≥18 and ≤85 years of age
  • The target AV fistula has undergone successful dialysis for at least 1 time
  • Patient has a de novo and/or non-stented restenotic lesion located in the outflow vein(Arteries and Central Vein are excluded)
  • Patient has a de novo and/or non-stented restenotic lesion(≥50% stenosis)and at least one of the following occurs:

    • The physical examination was abnormal
    • Significant increase in dynamic venous pressure
    • Blood flow decreased significantly
  • Patient has a target lesion or a tandem lesion that is ≤ 100 mm in length
  • Patient underwent successful crossing of the target lesion with the guide wire and pre-dilatation with a PTA balloon defined as:

    • Residual stenosis of ≤ 30% AND
    • Absence of a flow limiting dissection (Grade ≥C) or perforation
  • Patient provides written prior to enrollment in the study

Exclusion criteria

Exclusion Criteria:

  • Women who are breastfeeding, pregnant, or are intending to become pregnant, or men intending to father children
  • Dialysis access is located in the lower extremity
  • More than one lesion
  • Patient with hemodynamically significant central venous stenoses
  • Patient has presence of a stent located in the target AV access circuit
  • Patient has undergone prior intervention of access site within 30 days of index procedure
  • Patient with target AVF or access circuit which previously had or currently has a plan to surgery
  • Patient who cannot receive recommended antiplatelet and/or anticoagulant therapy
  • Patients undergoing immunotherapy or suspected/confirmed vasculitis
  • Patients with a history of coagulation dysfunction, thrombocytopenic purpura or RH-negative blood type
  • Patient has an infected AV access or systemic infection
  • Patient has a of \<24 months
  • Patient is anticipating a kidney transplant or with anticipated conversion to peritoneal dialysis
  • Patient has a co-morbid condition that, in the judgment of the Investigator, may cause him/her to be non-compliant with the protocol or confound the data interpretation
  • Patient is enrolled in another drug, device, or biologic study and has not completed the primary endpoint, or was previously enrolled in this study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
164 participants (estimated)

Study arms

  • Experimental
    DCB catheter

    Using DCB catheter for the treatment of subjects with a de novo or non-stented restenotic obstructive lesion located in the native arteriovenous dialysis fistulae.

    Device: DCB catheter

Interventions

  • DeviceDCB catheter

    Trade name of DCB catheter:Acoart Orchid&Dhalia

06

What researchers measure

Primary outcomes

  1. Target Lesion Primary Patency Rate

    Defined as freedom from clinically-driven target lesion revascularization (CD-TLR) or access circuit thrombosis measured.

    Time frame: 6 months

  2. Serious Adverse Event Rate

    Defined as the Serious Adverse Event (SAE) rate involving the AV access circuit.

    Time frame: 30 days

Secondary outcomes

  1. Target Lesion Primary Patency Rate

    Defined as freedom from CD-TLR or access thrombosis occurring in the target lesion post-procedure.

    Time frame: 12 months,24 months

  2. All-cause mortality Rate

    All-cause mortality post procedure

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2025, 34 months after the start.

Of 84 interventional studies with no phase under Arteriovenous Fistula, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 43. This study's planned 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2024
First posted
Jan 16, 2024
StartActual
Feb 20, 2023
Primary completionEst.
Dec 2025
CompletionEst.
Jun 2027
Last update
Jan 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06205576
Lead sponsor
Acotec Scientific Co., Ltd
Responsible party
Sponsor
First posted
Jan 16, 2024
Start date
Feb 20, 2023
Primary completion
Dec 2025 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jan 16, 2024

Study contacts

Wang Yu Zhu
Contact
wangyuzhu@163.com
010-82693657

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion